Overview
This study tested fexofenadine (an antihistamine) and prednisolone against palladium-induced allergic contact dermatitis in a murine model. Fexofenadine at 5 mg/kg achieved equivalent suppression to prednisolone at 50 mg/kg (the highest dose tested) without causing the weight loss and fur deterioration seen with high-dose prednisolone. The result suggests antihistamine therapy may provide effective management of Pd-induced delayed-type hypersensitivity without corticosteroid side effects.
Key numbers
- Fexofenadine doses tested: 5 and 10 mg/kg
- Prednisolone doses tested: 5, 10, 30, and 50 mg/kg
- Fexofenadine 5 mg/kg: equivalent suppression to prednisolone 50 mg/kg (no dose-dependent escalation for fexofenadine)
- Prednisolone 30 and 50 mg/kg: caused weight loss and poor fur condition
- Fexofenadine: no adverse effects observed at either dose
Methods (brief)
Murine Pd-induced ACD model with sensitization and challenge protocol. Treatment arms: fexofenadine at 5 and 10 mg/kg (oral), prednisolone at 5, 10, 30, and 50 mg/kg, and vehicle control. Footpad swelling measured as primary endpoint. Body weight and clinical observations recorded throughout.
Implications
This page makes the source discoverable for palladium evidence routing. Provides pharmacological intervention data showing antihistamine efficacy in Pd-induced delayed-type hypersensitivity in a murine model, with favorable safety profile compared to high-dose corticosteroids.
Related evidence
Update history
No substantive edit history is available in this build. The full commit record is available in git.